Skip to main content

Table 1 Biodistribution with 211At-A11 minibody

From: Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

Organ

1 h

5 h

5 h (NaClO4)

p value

9 h

9 h (NaClO4)

p value

23 h

42 h

 

Blood

20.1 ± 1.8

9.4 ± 0.9

9.1 ± 0.4

ns

3.2 ± 0.2

4.4 ± 0.6**

0.0090

1.3 ± 0.1

0.3 ± 0.0

 

Bone marrow

5.6 ± 1.0

N.D.

2.7 ± 0.6

N.D.

N.D.

N.D.

N.D.

 

Heart

6.7 ± 0.9

5.1 ± 0.7

4.4 ± 0.3

ns

2.3 ± 0.2

2.8 ± 0.5

ns

1.3 ± 0.2

0.3 ± 0.1

 

Lungs

11.3 ± 0.3

11.3 ± 2.0

7.3 ± 1.1*

0.0284

6.4 ± 1.0

5.6 ± 0.9

ns

4.0 ± 0.7

1.2 ± 0.2

 

Salivary glands

5.9 ± 0.7

14.7 ± 4.4

3.0 ± 0.7**

0.0067

13.4 ± 1.9

2.1 ± 0.3****

<0.0001

15.1 ± 3.4

4.2 ± 1.4

 

Throat

10.3 ± 4.6

12.3 ± 3.1

6.0 ± 0.1*

0.0187

10.4 ± 2.0

4.3 ± 0.7**

0.0011

14.3 ± 1.8

8.4 ± 4.8

 

Stomach

7.4 ± 2.1

17.4 ± 6.9

4.4 ± 0.7*

0.0251

15.7 ± 2.6

4.1 ± 1.1***

0.0002

13.7 ± 2.5

2.1 ± 0.9

 

Liver

9.9 ± 0.6

5.1 ± 0.7

3.1 ± 0.4**

0.0087

2.3 ± 0.3

1.9 ± 0.3

ns

1.6 ± 0.1

1.0 ± 0.1

 

Spleen

10.5 ± 1.5

9.7 ± 2.1

5.0 ± 1.2*

0.0181

4.8 ± 0.6

4.4 ± 1.2

ns

2.7 ± 0.2

1.6 ± 0.3

 

Kidneys

9.6 ± 0.8

6.6 ± 1.1

4.8 ± 0.8

ns

2.8 ± 0.3

2.9 ± 0.6

ns

1.9 ± 0.3

0.5 ± 0.0

 

Muscle

0.9 ± 0.2

0.9 ± 0.2

0.8 ± 0.2

ns

0.5 ± 0.1

0.8 ± 0.5

ns

0.3 ± 0.0

0.1 ± 0.1

 

Small intestine

4.1 ± 1.3

3.7 ± 0.3

2.7 ± 0.2**

0.0024

2.4 ± 0.7

1.7 ± 0.3

ns

1.7 ± 0.6

0.5 ± 0.2

 

Large intestine

2.0 ± 0.1

3.4 ± 0.5

2.1 ± 0.5*

0.0153

1.9 ± 0.1

1.5 ± 0.4

ns

1.3 ± 0.3

0.3 ± 0.2

 

Bladder

4.3 ± 1.3

11.4 ± 6.3

6.3 ± 1.7

ns

7.5 ± 4.6

5.7 ± 3.0

ns

2.8 ± 1.7

0.8 ± 0.3

 

Tumor

3.0 ± 0.2

7.2 ± 1.7

5.4 ± 1.5

ns

5.4 ± 2.5

5.6 ± 1.6

ns

5.6 ± 1.0

2.1 ± 0.6

 

Prostate

3.6 ± 0.6

11.1 ± 0.9

5.0 ± 0.9

ns

4.5 ± 0.4

3.5 ± 1.0

ns

5.0 ± 2.0

2.1 ± 0.7

 
  1. Uptake data (%IA/g ± SD) at different times after i.v. injection of 211At-A11 minibody. At 5 and 9 hpi, data is presented with and without NaClO4 pre-treatment.(n = 4) and difference between the groups, at 5 and 9 hpi respectively, analyzed using unpaired Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
  2. %IA/g Percent of injected activity per g; i.v. Intraveneous; ns Not significantly different; N.D. Not determined